XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue (Tables)
6 Months Ended
Jun. 30, 2024
Revenue  
Schedule of revenue recognized from collaborative arrangements

Three Months Ended June 30, 

Six Months Ended June 30, 

(In thousands)

2024

2023

2024

2023

Viatris collaboration agreement – Amounts receivable from Viatris

$

14,256

$

13,743

$

28,759

$

24,154

Three Months Ended June 30, 

Six Months Ended June 30, 

(In thousands)

  

2024

  

2023

    

2024

  

2023

YUPELRI net sales (Theravance Biopharma implied 35%)

$

19,085

$

19,263

$

38,415

$

35,697

Summary of the reductions to R&D costs related to reimbursement payments

Three Months Ended June 30, 

Six Months Ended June 30, 

(In thousands)

    

2024

    

2023

2024

    

2023

Viatris

$

296

$

1,947

$

485

$

3,700